Why do I have to pay for the SkinVision-Service?

We're glad you asked! At SkinVision, we're driven by transparency, honesty, and the deeply rooted mission to save lives by enabling early detection of skin cancer. 

Here's a breakdown of how your payment contributes to our mission and what it enables us to do:

• Expert Dermatological Insight: Your fees enable us to offer the expertise of our dedicated dermatologists. With a 90.5% sensitivity rate, our advanced algorithm is a critical tool in early skin cancer detection.
• Fighting Skin Cancer Together: Every check you perform with SkinVision is a step towards early skin cancer detection. Your choice to use SkinVision supports our mission to combat skin cancer, aiding us in saving lives every day.
• Commitment to Quality and Security: We’re proud to be a CE marked and TGA approved medical device, a testament to our commitment to maintaining the highest quality management systems (ISO 13485), to ensure we provide you a service of high efficacy and safety. In keeping your personal and health data safe and secure, we also continue to maintain our information security management systems (ISO 27001). To read more about SkinVision's Three ISO certifications, visit this link.
• Research and Continuous Improvement: SkinVision believes and is obligated as a medical device to implement an evidence-based approach to continuously measure the performance of the device and collect further evidence of its safety and effectiveness. 

Thus, we invest time, energy and money to ensure that our service is clinically validated so that we can bring you a product that is backed by clinical evidence. 

The SkinVision Service has been the object of multiple third party studies, performed by prestigious academic institutions, including Erasmus Medical Center of Rotterdam (EMC), Ludwig Maximilian University of Munich (LMU) and data published in influential journals such as the Journal of the European Academy of Dermatology and Venereology (JEADV) [1].

In 2022, Erasmus Medical Center (EMC) published a prospective Multicenter Diagnostic Accuracy Study further validating the performance of the SkinVision Service [2].

This study showed us that: 

SkinVision can detect 90.5% of Skin Cancer cases. To compare: the sensitivity of general practitioners ranges between 61% and 66% [3-5]. This complements previous research on SkinVision [1] showing Sensitivity up to 95%.

References:

[1] Udrea et al., 2019 - DOI: 10.1111/jdv.15935

[2] Sangers et al., 2022 - DOI: 10.1159/000520474

[3] Ahmadi et al., 2018 - DOI: 10.1111/jdv.14484

[4] Beecher et al., 2018 - DOI: 10.1007/s11845-018-1788-z

[5] Corbo et al., 2012 - DOI: 10.1177/120347541201600410